| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-074
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2002-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a2e1ac9d3abe7a5e010c73089431ea9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5897320bb297b2c784d218b167e09222 |
| publicationDate |
2004-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004009189-A1 |
| titleOfInvention |
Antimutagenic effects of ganoderma lucidum spores |
| abstract |
The present invention provides a method for fetal protection by orally administering germination activated Ganoderma lucidum spore powder (“GASP”) to pregnant mammals. GASP demonstrates prophylactic effects on fetal damage in pregnant mammals, particularly humans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006269568-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008038288-A1 |
| priorityDate |
2002-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |